Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2026-03-26 @ 3:17 PM
Ignite Modification Date:
2026-03-26 @ 3:17 PM
NCT ID:
NCT07464769
Eligibility Criteria:
Inclusion Criteria:
o Scheduled neurotoxic treatment in any of the following settings: Taxane cohort
* Breast cancer patients planned for either neoadjuvant or adjuvant taxane treatment Oxaliplatin cohort
* Rectal cancer patients planned for total neoadjuvant treatment including oxaliplatin
* Colorectal cancer patients planned for adjuvant chemotherapy including oxaliplatin, without prior neoadjuvant oxaliplatin treatment
* Understand written and oral Swedish.
Exclusion Criteria:
* Previous neurotoxic chemotherapy\* treatment
* Distant metastases
* Any psychiatric disorder or health disorder that causes an inability to make an informed consent to participate.
* Any manifest clinically significant peripheral neuropathy according to treating physician.
* Current lymphoedema in limbs requiring compression therapy.
* Ongoing pregnancy.
* Planned taxane or oxaliplatin treatment shorter than 8 weeks or longer than 26 weeks
* Planned compression or cryotherapy of hands and/or feet during taxane or oxaliplatin
* Taxanes (docetaxel, paclitaxel, nabpaclitaxel), platinum components (carboplatin, oxaplatin, cisplatin), vinca-alkaloids (vincristine, vinblastine, vinorelbine, eribulin), bortezomid, thalidomide, antibody drug conjugate including vedotin or emtansine.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT07464769
Study Brief:
Protocol Section:
NCT07464769